: Biogen halts development of antibody drug aimed at Alzheimer’s | Daily Traders Edge

: Biogen halts development of antibody drug aimed at Alzheimer’s

Back To Homepage

June 17

07:37 2021

Share it With Friends

Shares of Biogen Inc. fell nearly 1% in the extended session after the pharma company said it will halt the development of an antibody drug aimed at treating Alzheimer’s disease after a study showed no benefit to patients. Another of the company’s drugs aimed at the disease won approval earlier this month.

Continue Reading At MarketWatch

Related Articles

Scroll Back To Top

© Copyright Daily Traders Edge. All Rights reserved.
tastyworks, Inc. (“tastyworks”) has entered into a Market Agreement with Adam Mesh Trading (“Marketing Agent”) whereby tastyworks pays compensation to Marketing Agent to recommend tastyworks’ brokerage services. The existence of this Marketing Agreement should not be deemed as an endorsement or recommendation of Marketing Agent by tastyworks and/or any of its affiliated companies. Neither tastyworks nor any of its affiliated companies is responsible for the privacy practices of Marketing Agent or this website. tastyworks does not warrant the accuracy or content of the products or services offered by Marketing Agent or this website.